ProMIS Neurosciences Inc. (T:PMN*CA)

Business Focus: Bio Therapeutic Drugs

Aug 02, 2022 07:00 am ET
ProMIS Neurosciences Presents at 2022 Alzheimer’s Association International Conference
ProMIS Neurosciences Inc. (Nasdaq: PMN) (TSX: PMN), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative...
Jul 27, 2022 07:00 am ET
ProMIS Neurosciences to Present at 2022 Alzheimer’s Association International Conference
ProMIS Neurosciences Inc. (Nasdaq: PMN) (TSX: PMN), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers, implicated in the development of neurodegenerative...
Jul 08, 2022 07:00 am ET
ProMIS Neurosciences to Commence Trading on Nasdaq Under the Symbol “PMN”
ProMIS Neurosciences Inc. (Nasdaq: PMN) (TSX: PMN) (“ProMIS” or the “Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers, implicated in the...
Jun 27, 2022 07:00 am ET
PROMIS ANNOUNCES REVERSE SHARE SPLIT TO MEET NASDAQ LISTING CRITERIA
ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of potential therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative...
Jun 22, 2022 07:00 am ET
ProMIS Neurosciences Announces Authorization of Series 1 Preferred Shares
ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or the “Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers, implicated in the...
Jun 22, 2022 07:00 am ET
ProMIS Neurosciences Announces Debt Amendment and Conversion
ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or the “Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers, implicated in the...
Jun 22, 2022 07:00 am ET
ProMIS Neurosciences Announces Filing of Form 10 Registration Statement and Nasdaq Listing Application
ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or the “Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers, implicated in the...
May 17, 2022 07:00 am ET
ProMIS Neurosciences presents at the 2022 Neuro4D International Conference
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases,...
May 13, 2022 09:20 am ET
CORRECTION: ProMIS Neurosciences Announces First Quarter 2022 Results
There was an error at the end of the first paragraph. March 31, 2021 has been changed to March 31, 2022. There were no other changes to the release. Please find full corrected release below. ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF)...
May 13, 2022 07:00 am ET
ProMIS Holds Annual and Special Meeting of Shareholders All Resolutions Approved
ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or the “Corporation”), is pleased to announce the Annual and Special Meeting of Shareholders (the “Meeting”) of ProMIS was held online by virtual web-cast meeting, on Thursday, May 12,...
May 13, 2022 07:00 am ET
ProMIS Neurosciences Announces First Quarter 2022 Results
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or the “Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers, implicated in the...
May 03, 2022 07:00 am ET
Independent Proxy Advisory Firms, ISS and Glass Lewis, Recommend ProMIS Shareholders Vote FOR All Proposed Items at the Upcoming Annual and Special Meeting of Shareholders
ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or the “Company”) is pleased to announce that leading independent proxy advisory firms, Institutional Shareholder Services Inc. (“ISS”) and Glass Lewis & Co. (“Glass Lewis”) have each...
Apr 28, 2022 07:00 am ET
ProMIS Neurosciences Reports New Milestones in Potential Therapeutic Approaches for Amyotrophic Lateral Sclerosis (ALS)
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of potential therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative...
Apr 19, 2022 07:00 am ET
ProMIS appoints experienced industry veteran Larry Altstiel as Chief Medical Officer
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative...
Apr 18, 2022 09:05 am ET
Argus Research Initiates Equity Report Coverage on ProMIS Neurosciences, Inc. (TSX:PMN & OTCQB: ARFXF)
NEW YORK , April 18, 2022 /PRNewswire/ -- Argus Research, an independent investment research firm, has launched Argus Equity Report coverage on ProMIS Neurosciences, Inc. (TSX:PMN)
Apr 07, 2022 07:00 am ET
ProMIS Files Management Information Circular in Connection with Annual General and Special Meeting of Shareholders
ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or the “Corporation”), is pleased to announce it has mailed the Notice of Notice-and-Access (the “N&A Notice”) to shareholders of record of the Corporation as of April 01, 2022, in...
Apr 07, 2022 07:00 am ET
ProMIS Neurosciences Presents at the 2022 American Academy of Neurology Annual Meeting
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases,...
Mar 24, 2022 07:00 am ET
ProMIS Neurosciences to Present at the 10th Annual Neurodegenerative Drug Development Summit
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases,...
Mar 22, 2022 07:00 am ET
ProMIS Neurosciences Presents Preclinical Results of its Experimental Alzheimer’s Vaccine at the 2022 International AD/PDTM Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative...
Mar 17, 2022 07:00 am ET
ProMIS Neurosciences Announces Fiscal Year 2021 Results
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or the “Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers, implicated in the...
Mar 10, 2022 07:00 am ET
ProMIS Neurosciences to Present at the 2022 International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PDTM) and Related Neurological Disorders
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases,...
Mar 02, 2022 07:00 am ET
ProMIS Neurosciences’ PMN310 antibody demonstrates significant cognitive benefit in a mouse model of Alzheimer’s disease
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers, announced today that PMN310, its lead antibody...
Feb 03, 2022 07:00 am ET
ProMIS Neurosciences Appoints Renowned Neuroscientists, Dr. Guy Rouleau and Dr. Alain Dagher to its Scientific Advisory Board
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative...
Jan 27, 2022 07:00 am ET
ProMIS Neurosciences Appoints Internationally Recognized Neuroscientist Dr. Cheryl Wellington to its Scientific Advisory Board
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative...
Jan 18, 2022 07:00 am ET
ProMIS Neurosciences Announces Antibody Program for Schizophrenia Therapy and Recruitment of Dr. Carsten Korth to its Scientific Advisory Board
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative...
Jan 07, 2022 07:00 am ET
ProMIS Neurosciences to Participate in the Biotech Showcase 2022 Virtual Panel Discussion: Aduhelm Stimulating the Next Generation of Alzheimer’s Treatment
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative...
Jan 06, 2022 07:30 am ET
ProMIS Neurosciences to Participate in H.C. Wainwright BioConnect 2022 Virtual Conference
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative...
Dec 16, 2021 07:30 am ET
ProMIS Neurosciences Issues Chairman’s Memorandum
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, issued today a...
Dec 02, 2021 07:00 am ET
ProMIS Neurosciences Shareholders Approve Special Resolution
ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (the “Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, is...
Nov 17, 2021 07:00 am ET
A Second Independent Proxy Advisor, ISS, Recommends Promis Neurosciences Shareholders Vote for the Share Consolidation
ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (the “Company”), is pleased to announce that a second independent, third party proxy advisory firm, Institutional Shareholder Services (“ISS”), has recommended that shareholders vote FOR the share...
Nov 12, 2021 07:00 am ET
ProMIS Neurosciences Announces Third Quarter 2021 Results
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS or the Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative...
Nov 02, 2021 07:00 am ET
Glass Lewis Recommends ProMIS Neurosciences Shareholders Vote for the Share Consolidation at the Upcoming Special Meeting
ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (the “Company”), is pleased to announce that Glass Lewis & Co., LLC (“Glass Lewis”), an independent proxy advisory firm, has recommended that shareholders vote FOR the share consolidation at the...
Oct 22, 2021 07:00 am ET
ProMIS Neurosciences Announces Update to Senior Management Team
ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics selectively targeting toxic oligomers implicated in the development of neurodegenerative diseases,...
Oct 22, 2021 07:00 am ET
ProMIS Neurosciences Appoints Accomplished Biotech Executive, Dr. Maggie Shafmaster, to its Board of Directors
ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics selectively targeting toxic oligomers implicated in the development of neurodegenerative diseases,...
Oct 21, 2021 07:00 am ET
ProMIS Neurosciences Files Special Meeting Proxy Material
ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (the “Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, is...
Oct 07, 2021 07:00 am ET
ProMIS Neurosciences Announces Special Shareholder Meeting
ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (the “Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, is...
Sep 15, 2021 07:30 am ET
ProMIS Neurosciences to Present at the Second Annual Undruggable Leaders Forum, September 15-16, 2021
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, announced today...
Sep 13, 2021 07:30 am ET
ProMIS Neurosciences to Participate in H.C. Wainwright & Co. 23rd Annual Investment Conference
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, announced today...
Sep 01, 2021 07:30 am ET
ProMIS Neurosciences appoints accomplished biotechnology executive, Josh Mandel-Brehm, to its Board of Directors
ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics selectively targeting toxic oligomers implicated in the development of neurodegenerative diseases,...
Aug 25, 2021 09:44 am ET
ProMIS Neurosciences Closes Upsized US$20,125,000 Public Offering
ProMIS Neurosciences Inc. (TSX: PMN) (the “Company” or “ProMIS”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, is...
Aug 18, 2021 10:49 am ET
ProMIS Neurosciences Inc. Announces Upsize of Previously Announced Public Offering of Units to US$17.5M
ProMIS Neurosciences Inc.  (“ProMIS” or the “Company”) (TSX: PMN), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, is...
Aug 18, 2021 08:13 am ET
IIROC Trade Resumption - PMN
TORONTO, Aug. 18, 2021 /CNW/ - Trading resumes in:
Aug 18, 2021 07:10 am ET
ProMIS Neurosciences Inc. Announces Pricing of US$15 Million Public Offering of Units
ProMIS Neurosciences Inc.  (“ProMIS” or the “Company”) (TSX: PMN), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, is...
Aug 17, 2021 04:50 pm ET
IIROC Trading Halt - PMN
TORONTO, Aug. 17, 2021 /CNW/ - The following issues have been halted by IIROC:
Aug 17, 2021 04:40 pm ET
ProMIS Neurosciences Inc. Announces US$15 Million Offering of Units
ProMIS Neurosciences Inc. (“ProMIS” or the “Company”) (TSX: PMN), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, has...
Aug 12, 2021 07:30 am ET
ProMIS Neurosciences Announces Second Quarter 2021 Results
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS or the Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative...
Aug 04, 2021 07:30 am ET
ProMIS Neurosciences Issues Chairman’s Memorandum
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, issued today a...
Jul 22, 2021 07:15 am ET
ProMIS Neurosciences to Present at 2021 Alzheimer’s Association International Conference
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, will give two...
Jul 08, 2021 07:30 am ET
ProMIS Neurosciences Obtains Receipt for Final Base Shelf Prospectus
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (the “Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases,...
Jul 02, 2021 07:30 am ET
ProMIS Neurosciences Announces Results of Annual Meeting of Shareholders
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced...
Jun 08, 2021 07:30 am ET
ProMIS Neurosciences congratulates Biogen on FDA accelerated approval of aducanumab for Alzheimer’s disease
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today...
Jun 03, 2021 07:30 am ET
ProMIS Neurosciences Files Preliminary Short Form Base Shelf Prospectus
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (the “Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases,...
May 27, 2021 07:30 am ET
ProMIS Neurosciences appoints renowned scientist, Dr. David Wishart as Chief Physics Officer
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced...
May 25, 2021 07:30 am ET
ProMIS Neurosciences initiates commercialization of COVID-19 serology assay
ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics selectively targeting toxic oligomers implicated in the development of neurodegenerative diseases,...
May 21, 2021 08:30 am ET
ProMIS Neurosciences re-initiates path to IND for PMN310 with producer cell line development
ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics selectively targeting toxic oligomers implicated in the development of neurodegenerative diseases,...
May 19, 2021 06:30 am ET
ProMIS Neurosciences appoints accomplished biotechnology executive, Neil Warma, to its Board of Directors
ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics selectively targeting toxic oligomers implicated in the development of neurodegenerative diseases,...
May 14, 2021 07:00 am ET
ProMIS Neurosciences Announces First Quarter 2021 Results
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS or the Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative...
May 12, 2021 06:30 am ET
ProMIS Neurosciences appoints renowned neuroscientist, Dr. Rudolph Tanzi, as Chair of Scientific Advisory Board
ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics selectively targeting toxic oligomers implicated in the development of neurodegenerative diseases,...
Mar 31, 2021 07:30 am ET
ProMIS Neurosciences Announces Fiscal Year 2020 Results
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS or the Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative...
Mar 22, 2021 10:57 am ET
IIROC Trade Resumption - PMN
TORONTO, March 22, 2021 /CNW/ - Trading resumes in:
Mar 22, 2021 10:45 am ET
IIROC Trading Halt - PMN
TORONTO, March 22, 2021 /CNW/ - The following issues have been halted by IIROC:
Mar 22, 2021 10:44 am ET
ProMIS Neurosciences Completes US$7M (CDN$8.75M) Financing with Distinguished Group of Boston Based Investors
ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, is pleased to...
Feb 02, 2021 08:30 am ET
ProMIS Neurosciences Offers Perspectives on Recent Progress in the Alzheimer’s/Amyloid Field
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, announced today...
Jan 12, 2021 06:30 am ET
ProMIS Neurosciences Announces Strategic Priorities for 2021
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, announced today...
Nov 16, 2020 04:48 pm ET
ProMIS Neurosciences Completes Offering of Special Warrants
ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, is pleased to...
Nov 11, 2020 06:30 am ET
ProMIS Neurosciences Announces Third Quarter 2020 Results
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS or the Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative...
Nov 09, 2020 06:30 am ET
ProMIS Neurosciences offers comments on recent FDA Advisory Committee meeting on aducanumab for the treatment of Alzheimer’s disease
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today commented...
Nov 05, 2020 06:30 am ET
ProMIS Neurosciences Closes First Tranche of Private Placement
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, is pleased to...
Oct 30, 2020 06:30 am ET
ProMIS Neurosciences’ Dr. Neil Cashman CSO, to Speak at 2020 ALS ONE Research Symposium
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, announced today...
Oct 29, 2020 06:30 am ET
ProMIS Neurosciences adds Dr. David Wishart to its Scientific Advisory Board
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, welcomes Dr....
Oct 23, 2020 06:30 am ET
ProMIS Neurosciences Announces Up to $3 Million Private Placement Offering of Special Warrants
ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, is pleased to...
Oct 21, 2020 06:30 am ET
ProMIS Neurosciences Offers its Perspective on the Likelihood of Regulatory Approval of Aducanumab
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, released a white...
Oct 13, 2020 06:30 am ET
ProMIS Neurosciences’ Neil Cashman to Speak at Protein Misfolding Drug Discovery Conference
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, announced today...
Sep 22, 2020 06:30 am ET
ProMIS Neurosciences to develop multivalent vaccine for Alzheimer’s disease
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, announced today...
Sep 10, 2020 06:30 am ET
ProMIS Neurosciences to Participate in H.C. Wainwright & Co. 22nd Annual Investment Conference
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, announced today...
Aug 13, 2020 06:30 am ET
ProMIS Neurosciences Announces Second Quarter 2020 Results
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS or the Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative...
Jul 29, 2020 01:17 pm ET
ProMIS Neurosciences Announces Results of Annual Meeting of Shareholders
ProMIS Neurosciences, Inc. (the "Corporation") (TSX: PMN; OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative...
Jul 09, 2020 06:30 am ET
ProMIS Neurosciences and BC Neuroimmunology announce revenue-sharing joint venture agreement to develop and offer blood-based diagnostic tests for Alzheimer’s disease
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a company with unique, core technology to predict novel targets (peptide antigens) on the molecular surface of complex, misfolded proteins, and BC Neuroimmunology Lab (BCNI), have entered into a...
Jun 24, 2020 06:30 am ET
ProMIS Neurosciences announces adjournment and change of location of annual meeting of shareholders
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, announces that...
Jun 17, 2020 06:30 am ET
ProMIS Neurosciences and collaborator BC Neuroimmunology announce significant progress on development of highly accurate antibody test for COVID-19
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a company with unique, core technology to predict novel targets on the molecular surface of complex proteins, and its collaborator BC Neuroimmunology Lab Inc. (BCNI), have created a highly...
May 28, 2020 06:30 am ET
ProMIS Neurosciences and collaborative team receive Supercluster Award supporting avoidance of future pandemics by new strains of the COVID-19 virus
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a company with unique core technology to predict novel targets on the molecular surface of complex proteins, together with a team of commercial and academic collaborators, have received a...
May 20, 2020 06:30 am ET
ProMIS Neurosciences Chairman’s Update details new programs from expanded use of novel technology platform
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, has released a...
May 19, 2020 06:30 am ET
ProMIS Neurosciences and BC Neuroimmunology expand collaboration to develop and commercialize proprietary diagnostic assays
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a company with unique, core technology to predict novel targets on the molecular surface of complex proteins, announced today that, in addition to its ongoing program to develop a...
May 13, 2020 06:30 am ET
ProMIS Neurosciences Announces First Quarter 2020 Results
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS or the Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative...
May 12, 2020 06:30 am ET
ProMIS Neurosciences identifies multiple novel targets on SARS CoV-2 for development of a highly accurate COVID-19 antibody test
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a company with unique, core technology to predict novel targets on the molecular surface of complex proteins, has advanced its program to develop a high-throughput, highly accurate test for...
May 06, 2020 06:30 am ET
ProMIS Neurosciences develops novel antagonists for RACK1, a protein involved in numerous neurodegenerative diseases, including ALS
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, has identified...
Apr 30, 2020 06:30 am ET
ProMIS Neurosciences creates novel intrabodies for ALS, frontotemporal dementia and other neurodegenerative diseases
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, has generated...
Apr 22, 2020 02:43 pm ET
ProMIS Neurosciences commends Biogen for clarifying aducanumab regulatory filing
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, applauds Biogen’s...
Apr 15, 2020 06:30 am ET
ProMIS Neurosciences announces collaboration to develop serological test to assess COVID-19 immunity
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a company with a unique, core technology to predict novel targets on the molecular surface of complex proteins, announced today a collaboration with Dr. Hans Frykman and his team to develop a...
Apr 09, 2020 06:30 am ET
Journal of the American Academy of Neurology Publishes ProMIS Neurosciences’ Abstracts on Novel Antibody Candidates
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers of proteins implicated in the development of neurodegenerative diseases,...
Apr 07, 2020 06:30 am ET
ProMIS Neurosciences to Present Data and Moderate Session at AAIC 2020
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, announced today...
Mar 24, 2020 06:30 am ET
PROMIS NEUROSCIENCES ANNOUNCES APPROVAL FOR WARRANT REPRICING
ProMIS Neurosciences, Inc. (“ProMIS” or the “Company”) (TSX: PMN) (OTCQB: ARFXF) announces that the Company has received approval from the Toronto Stock Exchange to amend the exercise price of an aggregate of 44,182,530 outstanding common share...
Mar 18, 2020 06:30 am ET
ProMIS Neurosciences Announces Fiscal Year 2019 Annual Results
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS or the Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative...
Feb 26, 2020 06:30 am ET
ProMIS Neurosciences Initiates Natural History Study of Blood-Based Biomarkers in Alzheimer’s Disease
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), with Toronto Memory Program, Canada’s largest and most experienced memory clinic and site for drug treatment trials in Alzheimer’s disease (AD) has initiated a pilot longitudinal study to assess...
Feb 25, 2020 06:30 am ET
ProMIS Neurosciences Announces Gross Proceeds of $1,257,970 Related to the Exercise of Common Stock Warrants
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, is pleased to...
Feb 11, 2020 06:30 am ET
ProMIS Neurosciences to Participate in Noble Capital Markets 16th Annual Investor Conference
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, announced today...
Feb 06, 2020 06:30 am ET
ProMIS Neurosciences to Participate in the BIO CEO & Investor Conference
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, announced today...
Jan 29, 2020 06:30 am ET
ProMIS Neurosciences Data for Alzheimer’s Disease Program Targeting Tau Accepted for Presentation at Tau2020
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, announced today...
Jan 15, 2020 06:30 am ET
ProMIS Neurosciences Appoints Dr. José Luis Molinuevo to its Scientific Advisory Board
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, has welcomed José...
Jan 09, 2020 06:30 am ET
ProMIS Neurosciences to present at Sachs 3rd Annual Neuroscience Innovation Forum
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced...
Jan 08, 2020 06:30 am ET
ProMIS Neurosciences issues Chairman’s Update detailing positive outlook for Alzheimer’s disease therapy, pipeline in 2020
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, issued today a...
Dec 31, 2019 01:54 pm ET
ProMIS Neurosciences Completes Second Closing of Private Placement
ProMIS Neurosciences, Inc. (“ProMIS” or the “Company”) (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative...
Dec 10, 2019 07:30 am ET
ProMIS Neurosciences’ Alzheimer’s disease program takes on renewed significance following positive aducanumab news
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, has issued a...
Dec 05, 2019 12:50 pm ET
Aducanumab is good; next generation Alzheimer’s disease therapies will be better
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, commends Biogen...
Nov 18, 2019 06:30 am ET
ProMIS Neurosciences Completes First Closing of Private Placement
/NOT FOR DISTRIBUTION TO US NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
Nov 14, 2019 06:30 am ET
ProMIS Neurosciences Announces Third Quarter 2019 Results
Company continues to expand its portfolio of highly selective antibodies targeting root cause of Alzheimer's, ALS and Parkinson's disease
Nov 14, 2019 06:30 am ET
ProMIS Neurosciences Announces Third Quarter 2019 Results
Company continues to expand its portfolio of highly selective antibodies targeting root cause of Alzheimer's, ALS and Parkinson's disease
Nov 13, 2019 06:30 am ET
ProMIS Neurosciences Undertaking $6.5M Private Placement
/NOT FOR DISTRIBUTION TO US NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES./
Nov 07, 2019 06:30 am ET
ProMIS Neurosciences outlines best-in-class approach to amyloid-beta-targeting drug candidates for Alzheimer's disease
Dr. Johanne Kaplan highlights need for precision selectivity for the toxic form of amyloid beta in narrated overview
Nov 07, 2019 06:30 am ET
ProMIS Neurosciences outlines best-in-class approach to amyloid-beta-targeting drug candidates for Alzheimer's disease
Dr. Johanne Kaplan highlights need for precision selectivity for the toxic form of amyloid beta in narrated overview
Oct 24, 2019 03:00 am ET
ProMIS Neurosciences issues Chairman's update memorandum and white paper on Alzheimer's disease
New resources detail positive impact of aducanumab pivotal trial results and recent progress of ProMIS pipeline programs
Oct 24, 2019 03:00 am ET
ProMIS Neurosciences issues Chairman's update memorandum and white paper on Alzheimer's disease
New resources detail positive impact of aducanumab pivotal trial results and recent progress of ProMIS pipeline programs
Oct 23, 2019 09:49 am ET
ProMIS Neurosciences advances ALS program selectively targeting toxic form of TDP-43
Results follow recent updates to ProMIS antibody programs selectively targeting root cause of multiple neurodegenerative diseases
Oct 23, 2019 07:30 am ET
ProMIS Neurosciences advances ALS program selectively targeting toxic form of TDP-43
Results follow recent updates to ProMIS antibody programs selectively targeting root cause of multiple neurodegenerative diseases
Oct 17, 2019 07:30 am ET
ProMIS Neurosciences advances Alzheimer's disease program targeting neurotoxic forms of tau
Data show antibody candidates bind toxic forms of tau and inhibit its propagation in a cellular model
Oct 17, 2019 07:30 am ET
ProMIS Neurosciences advances Alzheimer's disease program targeting neurotoxic forms of tau
Data show antibody candidates bind toxic forms of tau and inhibit its propagation in a cellular model
Oct 08, 2019 07:30 am ET
ProMIS Neurosciences Identifies Novel Antibody Candidates for Multiple System Atrophy
Antibodies show highly selective binding to pathogenic forms of alpha-synuclein implicated in multiple system atrophy
Oct 08, 2019 07:30 am ET
ProMIS Neurosciences Identifies Novel Antibody Candidates for Multiple System Atrophy
Antibodies show highly selective binding to pathogenic forms of alpha-synuclein implicated in multiple system atrophy
Sep 03, 2019 07:30 am ET
ProMIS Neurosciences to Present at HC Wainwright Investment Conference
Company to showcase its innovative Alzheimer's, Parkinson's and ALS programs
Sep 03, 2019 07:30 am ET
ProMIS Neurosciences to Present at HC Wainwright Investment Conference
Company to showcase its innovative Alzheimer's, Parkinson's and ALS programs
Aug 27, 2019 07:30 am ET
ProMIS Neurosciences Appoints Internationally Recognized Researcher in Alzheimer's Disease in Down Syndrome Dr. Andre Strydom to its Scientific Advisory Board
TORONTO and CAMBRIDGE, MA, Aug. 27, 2019 /CNW/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, has added Dr. Andre Strydom to its scientific advisory board (SAB). Dr. Strydom is a world-recognized expert in ageing-related issues in Down syndrome and his research has advanced understanding of Alzheimer's disease (AD) in Down syndrome patients. His expertise and advocacy will help guide ProMIS development plans
Aug 27, 2019 07:30 am ET
ProMIS Neurosciences Appoints Internationally Recognized Researcher in Alzheimer's Disease in Down Syndrome Dr. Andre Strydom to its Scientific Advisory Board
TORONTO and CAMBRIDGE, MA, Aug. 27, 2019 /PRNewswire/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, has added Dr. Andre Strydom to its scientific advisory board (SAB). Dr. Strydom is a world-recognized expert in ageing-related issues in Down syndrome and his research has advanced understanding of Alzheimer's disease (AD) in Down syndrome patients. His expertise and advocacy will help guide ProMIS development
Aug 13, 2019 07:30 am ET
ProMIS Neurosciences Announces Second Quarter 2019 Results
Company continues to expand its portfolio of highly selective antibodies targeting root cause of Alzheimer's, ALS and Parkinson's disease
Aug 13, 2019 07:30 am ET
ProMIS Neurosciences Announces Second Quarter 2019 Results
Company continues to expand its portfolio of highly selective antibodies targeting root cause of Alzheimer's, ALS and Parkinson's disease
Jul 24, 2019 07:30 am ET
ProMIS Neurosciences Announces Results of Annual Meeting of Shareholders
ProMIS' shareholders show overwhelming support for all resolutions
Jul 18, 2019 03:00 pm ET
ProMIS Neurosciences Highlights Data for PMN310 at AAIC 2019
Alzheimer's Association International Conference includes oral session on PMN310 for Alzheimer's disease and poster presentation on ALS
Jul 18, 2019 03:00 pm ET
ProMIS Neurosciences Highlights Data for PMN310 at AAIC 2019
Alzheimer's Association International Conference includes oral session on PMN310 for Alzheimer's disease and poster presentation on ALS
Jul 10, 2019 07:30 am ET
Jul 10, 2019 07:30 am ET
Jul 09, 2019 07:30 am ET
ProMIS Neurosciences' Data for Alzheimer's Disease Clinical Candidate PMN310 Published in Scientific Reports
Nature Research Journal highlights data supporting the therapeutic potential of PMN310 against the toxic oligomer form of amyloid beta, a root cause of Alzheimer's disease
Jul 09, 2019 07:30 am ET
ProMIS Neurosciences' Data for Alzheimer's Disease Clinical Candidate PMN310 Published in Scientific Reports
Nature Research Journal highlights data supporting the therapeutic potential of PMN310 against the toxic oligomer form of amyloid beta, a root cause of Alzheimer's disease
Jun 27, 2019 07:30 am ET
Jun 27, 2019 07:30 am ET
ProMIS Neurosciences’ PMN310 Shows Greater Therapeutic Potential vs. Other Amyloid-Beta-Directed Antibodies
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, presented data...
Jun 26, 2019 07:30 am ET
ProMIS Neurosciences Closing Private Placement
/NOT FOR DISTRIBUTION TO US NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
Jun 19, 2019 07:30 am ET
ProMIS Neurosciences Appoints Renowned Parkinson's Disease Expert Dr. C. Warren Olanow to Scientific Advisory Board
Internationally recognized leader in neurodegenerative diseases to advise on programs selectively targeting the toxic oligomer
Jun 05, 2019 07:30 am ET
ProMIS Neurosciences Presents Lead Program for Alzheimer's Disease at Prestigious Keystone Symposia Scientific Conference
Neurodegenerative Diseases: New Insights and Therapeutic Opportunities to advance discussion about therapies for Alzheimer's disease among world's leading researchers
May 29, 2019 07:30 am ET
ProMIS Neurosciences' Eugene Williams to Present at JLABS' Conference on Innovations in Neurodegenerative Diseases
TORONTO and CAMBRIDGE, MA, May 29, 2019 /CNW/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, is participating in the JLABS @ Toronto conference, "Science 1st: Common Pathways and Mechanisms in Neurodegenerative Diseases" on May 30, 2019. Executive Chairman Eugene Williams will speak at the event, joining speakers from Sunnybrook Research Institute, the University of Toronto, including the Tanz Centre for Rese
May 28, 2019 07:30 am ET
ProMIS Neurosciences Identifies Novel Antibodies for Alzheimer's Disease with Selectivity for the Neurotoxic Form of Tau
Pipeline offers critical "one-two punch" in potential treatment arsenal for Alzheimer's disease
May 28, 2019 07:30 am ET
ProMIS Neurosciences Identifies Novel Antibodies for Alzheimer's Disease with Selectivity for the Neurotoxic Form of Tau
Pipeline offers critical "one-two punch" in potential treatment arsenal for Alzheimer's disease
May 14, 2019 07:30 am ET
ProMIS Neurosciences Announces First Quarter 2019 Results
Company continues to show significant progress on developing highly selective antibodiestargeting root cause of Alzheimer's and Parkinson's diseases and ALS
May 14, 2019 07:30 am ET
ProMIS Neurosciences Announces First Quarter 2019 Results
Company continues to show significant progress on developing highly selective antibodiestargeting root cause of Alzheimer's and Parkinson's diseases and ALS
Apr 23, 2019 07:30 am ET
ProMIS Neurosciences to Participate in the Think Equity Investor Conference
Company to showcase its innovative Alzheimer's, Parkinson's and ALS programs
Apr 23, 2019 07:30 am ET
ProMIS Neurosciences to Participate in the Think Equity Investor Conference
Company to showcase its innovative Alzheimer's, Parkinson's and ALS programs
Mar 27, 2019 08:00 am ET
Positive Results and New Technology Give Rise to Antibody Dominance
Investorideas.com, a leading investor news resource covering biotech and pharma stocks releases a snapshot looking at the biopharmaceutical market and how monoclonal antibody research is gaining market dominance. GELifesciences.com, talking about...
Mar 26, 2019 07:30 am ET
ProMIS Neurosciences to Participate in Microcap Spring Investor Summit 2019
Company to showcase innovative programs addressing urgent need for disease-modifying therapies selectively targeting toxic oligomers in Alzheimer's and Parkinson's diseases and ALS
Mar 26, 2019 07:30 am ET
ProMIS Neurosciences to Participate in Microcap Spring Investor Summit 2019
Company to showcase innovative programs addressing urgent need for disease-modifying therapies selectively targeting toxic oligomers in Alzheimer's and Parkinson's diseases and ALS
Mar 21, 2019 02:47 pm ET
Aducanumab Failure: Selectivity for the Toxic Oligomer is Essential to Treating Root Cause of Alzheimer's Disease
Discontinued aducanumab phase 3 studies emphasize urgent need for therapies that target the toxic oligomer with exacting precision
Mar 21, 2019 02:47 pm ET
Aducanumab Failure: Selectivity for the Toxic Oligomer is Essential to Treating Root Cause of Alzheimer's Disease
Discontinued aducanumab phase 3 studies emphasize urgent need for therapies that target the toxic oligomer with exacting precision
Mar 19, 2019 07:30 am ET
ProMIS Neurosciences to Present Data for Potential Best-in-Class Antibody Candidates for Parkinson's Disease at AD/PD™ 2019 Conference
Selected for podium presentation: novel antibody candidates bind only the toxic species of alpha-synuclein offering potential advantages over less selective therapies in development 
Mar 19, 2019 07:30 am ET
ProMIS Neurosciences to Present Data for Potential Best-in-Class Antibody Candidates for Parkinson's Disease at AD/PD™ 2019 Conference
Selected for podium presentation: novel antibody candidates bind only the toxic species of alpha-synuclein offering potential advantages over less selective therapies in development 
Mar 15, 2019 07:30 am ET
ProMIS Neurosciences Announces Fiscal Year 2018 Annual Results
TORONTO, ON and CAMBRIDGE, MA, March 15, 2019 /CNW/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced its operational and financial results for the year ended December 31, 2018.
Mar 15, 2019 07:30 am ET
ProMIS Neurosciences Announces Fiscal Year 2018 Annual Results
TORONTO, ON and CAMBRIDGE, MA, March 15, 2019 /PRNewswire/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced its operational and financial results for the year ended December 31, 2018.
Feb 21, 2019 06:30 am ET
ProMIS Neurosciences Adds Pharmaceutical Leader Timothy Rothwell to Board of Advisors
Former Sanofi U.S. Chairman to provide guidance and assistance to ProMIS business development strategies and partnering plans
Feb 21, 2019 06:30 am ET
ProMIS Neurosciences Adds Pharmaceutical Leader Timothy Rothwell to Board of Advisors
Former Sanofi U.S. Chairman to provide guidance and assistance to ProMIS business development strategies and partnering plans
Feb 12, 2019 06:30 am ET
Jan 31, 2019 06:30 am ET
Selectivity for the Toxic Oligomer Essential to Treating Root Cause of Alzheimer's Disease
Discontinued crenezumab phase 3 studies underscore urgent need for therapies that target the toxic oligomer with extraordinary precision
Jan 31, 2019 06:30 am ET
Selectivity for the Toxic Oligomer Essential to Treating Root Cause of Alzheimer's Disease
Discontinued crenezumab phase 3 studies underscore urgent need for therapies that target the toxic oligomer with extraordinary precision
Jan 23, 2019 06:30 am ET
ProMIS Neurosciences Completes Private Placement of Units
/NOT FOR DISTRIBUTION TO US NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES./
Jan 17, 2019 06:30 am ET
ProMIS Neurosciences to Participate in NobleCon15 and CanTech Investment Conferences
Company to showcase its innovative Alzheimer's, Parkinson's and ALS programs
Jan 17, 2019 06:30 am ET
ProMIS Neurosciences to Participate in NobleCon15 and CanTech Investment Conferences
Company to showcase its innovative Alzheimer's, Parkinson's and ALS programs
Dec 18, 2018 06:30 am ET
ProMIS Neurosciences to Present at Sachs Associates Neuroscience Innovation Forum and China [email protected]
ProMIS to showcase its Alzheimer's, Parkinson's and ALS programs at notable biotech investor events
Dec 18, 2018 06:30 am ET
ProMIS Neurosciences to Present at Sachs Associates Neuroscience Innovation Forum and China [email protected]
ProMIS to showcase its Alzheimer's, Parkinson's and ALS programs at notable biotech investor events
Dec 17, 2018 06:30 am ET
ProMIS Neurosciences Appoints Renowned Neuroscientist, Dr. Rudolph Tanzi, to Scientific Advisory Board
TORONTO and CAMBRIDGE, MA, Dec. 17, 2018 /CNW/ - ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics selectively targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced the appointment of Rudolph Tanzi, Ph.D, to the Company's scientific advisory board (SAB). Dr. Tanzi is the Joseph P. and Rose F. Kennedy Professor of Neurology at Harvard University and Vice-Chair of Neurology, Director of the Genetics and Aging Research Unit, and Co-Director of the Henry
Dec 17, 2018 06:30 am ET
ProMIS Neurosciences Appoints Renowned Neuroscientist, Dr. Rudolph Tanzi, to Scientific Advisory Board
TORONTO and CAMBRIDGE, MA, Dec. 17, 2018 /PRNewswire/ - ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics selectively targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced the appointment of Rudolph Tanzi, Ph.D, to the Company's scientific advisory board (SAB). Dr. Tanzi is the Joseph P. and Rose F. Kennedy Professor of Neurology at Harvard University and Vice-Chair of Neurology, Director of the Genetics and Aging Research Unit, and Co-Director of th
Nov 20, 2018 06:30 am ET
ProMIS Neurosciences Issues Year-to Date Update, Highlighting 2018 Accomplishments
Development of therapeutic antibodies for Alzheimer's disease, Parkinson's disease and ALS are top priorities for drug development and potential partnering
Nov 20, 2018 06:30 am ET
ProMIS Neurosciences Issues Year-to Date Update, Highlighting 2018 Accomplishments
Development of therapeutic antibodies for Alzheimer's disease, Parkinson's disease and ALS are top priorities for drug development and potential partnering
Nov 13, 2018 06:30 am ET
ProMIS Neurosciences Announces Third Quarter 2018 Results
TORONTO and CAMBRIDGE, MA, Nov. 13, 2018 /CNW/ - ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced its operational and financial results for the three and nine months ended September 30, 2018.
Nov 13, 2018 06:30 am ET
ProMIS Neurosciences Announces Third Quarter 2018 Results
TORONTO and CAMBRIDGE, MA, Nov. 13, 2018 /PRNewswire/ - ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced its operational and financial results for the three and nine months ended September 30, 2018.
Nov 06, 2018 06:30 am ET
ProMIS Neurosciences Discusses Critical Importance of Selectively Targeting the Root Cause of Alzheimer's Disease
Narrated white paper reveals lessons learned from 15 years of drug development; pressing need to selectively target the toxic oligomer
Nov 06, 2018 06:30 am ET
ProMIS Neurosciences Discusses Critical Importance of Selectively Targeting the Root Cause of Alzheimer's Disease
Narrated white paper reveals lessons learned from 15 years of drug development; pressing need to selectively target the toxic oligomer
Oct 31, 2018 07:30 am ET
ProMIS Neurosciences Identifies Novel Targets on Tau Protein Involved in the Development of Alzheimer's Disease and Other Dementias
ProMIS' proprietary discovery platform generates additional potential opportunities for pharma partnering
Oct 31, 2018 07:30 am ET
ProMIS Neurosciences Identifies Novel Targets on Tau Protein Involved in the Development of Alzheimer's Disease and Other Dementias
ProMIS' proprietary discovery platform generates additional potential opportunities for pharma partnering
Oct 11, 2018 07:30 am ET
ProMIS Neurosciences Identifies Novel Antibody Drug Candidates for Parkinson's Disease
Unique discovery platform generates new antibody candidates that block a root cause of Parkinson's Disease
Oct 11, 2018 07:30 am ET
ProMIS Neurosciences Identifies Novel Antibody Drug Candidates for Parkinson's Disease
Unique discovery platform generates new antibody candidates that block a root cause of Parkinson's Disease
Sep 17, 2018 07:30 am ET
ProMIS Neurosciences to Present at Extraordinary Futures Investment Conference
TORONTO and CAMBRIDGE, MA, Sept. 17, 2018 /CNW/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced that it will be featured as a presenting company at the Extraordinary Futures Investment Conference, sponsored by Cambridge House. The conference is being held on September 19-20, 2018 at the Vancouver Convention Centre East in Vancouver, British Columbia.
Sep 17, 2018 07:30 am ET
ProMIS Neurosciences to Present at Extraordinary Futures Investment Conference
TORONTO and CAMBRIDGE, MA, Sept. 17, 2018 /PRNewswire/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced that it will be featured as a presenting company at the Extraordinary Futures Investment Conference, sponsored by Cambridge House. The conference is being held on September 19-20, 2018 at the Vancouver Convention Centre East in Vancouver, British Columbia.
Sep 13, 2018 07:30 am ET
ProMIS Neurosciences Appoints James Kupiec, MD as Chief Medical Officer
Dr. Kupiec to leverage neurodegenerative experience from prior senior positions at Pfizer and Sanofi-Synthelabo
Sep 13, 2018 07:30 am ET
ProMIS Neurosciences Appoints James Kupiec, MD as Chief Medical Officer
Dr. Kupiec to leverage neurodegenerative experience from prior senior positions at Pfizer and Sanofi-Synthelabo
Aug 29, 2018 07:30 am ET
ProMIS Neurosciences Issues Narrated Overview of Second Quarter 2018 Results
TORONTO and CAMBRIDGE, MA, Aug. 29, 2018 /CNW/ - ProMIS Neurosciences, Inc. (TSX: PMN; OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced it has issued a narrated overview of second quarter 2018 operational results.
Aug 29, 2018 07:30 am ET
ProMIS Neurosciences Issues Narrated Overview of Second Quarter 2018 Results
TORONTO and CAMBRIDGE, MA, Aug. 29, 2018 /PRNewswire/ - ProMIS Neurosciences, Inc. (TSX: PMN; OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced it has issued a narrated overview of second quarter 2018 operational results.
Aug 22, 2018 07:30 am ET
ProMIS Neurosciences to Present at 20th Annual Global Investment Conference
TORONTO and CAMBRIDGE, MA, Aug. 22, 2018 /CNW/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics selectively targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced that it will be featured as a presenting company at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C.Wainwright & Co.  The conference is being held on September 4-6, 2018 at the St Regis New York Hotel in New York City.
Aug 22, 2018 07:30 am ET
ProMIS Neurosciences to Present at 20th Annual Global Investment Conference
TORONTO and CAMBRIDGE, MA, Aug. 22, 2018 /PRNewswire/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics selectively targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced that it will be featured as a presenting company at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C.Wainwright & Co.  The conference is being held on September 4-6, 2018 at the St Regis New York Hotel in New York City.
Aug 14, 2018 07:30 am ET
Aug 14, 2018 07:30 am ET
Jul 10, 2018 07:30 am ET
Jul 10, 2018 07:30 am ET
Jun 28, 2018 07:30 am ET
ProMIS Neurosciences Announces Results of Annual Meeting of Shareholders
ProMIS' shareholders show overwhelming support for all resolutions
Jun 28, 2018 07:30 am ET
ProMIS Neurosciences Announces Results of Annual Meeting of Shareholders
ProMIS' shareholders show overwhelming support for all resolutions
Jun 26, 2018 07:30 am ET
ProMIS Neurosciences Unique Discovery Platform Generates Potential New Antibody Therapeutics for Neurodegenerative Diseases
Antibody Candidates Targeting Toxic Oligomers Implicated in Parkinson's Disease and Amyotrophic Lateral Sclerosis (ALS) Advance to the Final Stage of ProMIS Discovery Platform
Jun 26, 2018 07:30 am ET
ProMIS Neurosciences Unique Discovery Platform Generates Potential New Antibody Therapeutics for Neurodegenerative Diseases
Antibody Candidates Targeting Toxic Oligomers Implicated in Parkinson's Disease and Amyotrophic Lateral Sclerosis (ALS) Advance to the Final Stage of ProMIS Discovery Platform
Jun 25, 2018 03:57 pm ET
ProMIS Neurosciences Inc., Treating the Root Cause of Alzheimer's, CEO Clip Video
Vancouver, British Columbia--(Newsfile Corp. - June 25, 2018) - Dr. Elliot Goldstein, President & CEO of ProMIS Neurosciences speaks on the company's developing treatments for Alzheimer's and other neurodegenerative diseases.
Jun 20, 2018 07:30 am ET
ProMIS Neurosciences Reminds Shareholders of June 25th Voting Cut-Off for Upcoming Annual General Meeting
TORONTO and CAMBRIDGE, MA, June 20, 2018 /CNW/ - ProMIS Neurosciences Inc. (the "Corporation") (TSX: PMN.TO) (OTCQB: ARFXF) would like to remind shareholders they have until 9:00 am (Toronto Time) on Monday June 25, 2018 to vote their shares for the upcoming Annual General Meeting of shareholders to be held 9:00 am (Toronto Time) on Wednesday June 27, 2018.

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.